Zynext Ventures, the venture capital branch of Zydus Lifesciences, has made a strategic investment in neuro42, a company that specializes in developing portable MRI systems for neuroimaging and medical interventions. Neuro42’s technology aims to bring advanced MRI capabilities directly to the patient’s bedside, offering a compact and user-friendly system that can significantly expedite diagnosis and treatment. The company is also working on a robotic intervention module intended to improve procedures such as brain biopsies and ablations. While the portable MRI system has already received FDA 510(K) clearance for neuroimaging, neuro42 is seeking further regulatory approval for its interventional technology.
This investment underscores Zynext Ventures’ focus on supporting disruptive innovations in the healthcare sector. By backing neuro42, Zynext Ventures is helping to accelerate the development and deployment of these novel imaging and treatment solutions, which have the potential to reshape the field of neuroimaging and surgical interventions.
Image Credit: neuro42